For U.S. Healthcare Professionals Only
For U.S. Healthcare Professionals Only

CONTACT MY REP

TLS IS THE MOST COMMON DISEASE-RELATED EMERGENCY IN HEMATOLOGIC CANCERS1

37% of patients with hematologic malignancies developed TLS per year from 2010 to 20142

  • This is based on data from the National Inpatient Sample Database, the largest publicly available all-payer inpatient database
  • A total of 15,051 cases of TLS were identified among the 40,494 patients with hematologic malignancies during this period

Incidence of TLS in patients with hematologic malignancies2

37% incidence of TLS per year from 2010-2014 37% incidence of TLS per year from 2010-2014

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend to best manage TLS, anticipate it and initiate treatment prior to anticancer therapy for patients with CLL/SLL, B-cell lymphoma, and ALL3,4

CLL/SLL=chronic lymphocytic leukemia/small lymphocytic lymphoma; ALL=acute lymphoblastic leukemia.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose 

Back to the top